• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sanofi names chief scientific officer Gary Nabel as Sanofi Ebola response coordinator

Sanofi names chief scientific officer Gary Nabel as Sanofi Ebola response coordinator

November 24, 2014
CenterWatch Staff

As part of its contribution to the global response to the Ebola epidemic, Sanofi has appointed chief scientific officer Dr. Gary J. Nabel, M.D., Ph.D., as its Ebola response coordinator.

In his mission, Dr. Nabel will identify how Sanofi can help advance countermeasures to contain the current outbreak and prioritize and foster opportunities to develop novel treatments for the future.

"Given his past experience in public health epidemics as director of the NIH Vaccine Research Center and his leadership in developing an Ebola vaccine at NIH, Nabel is uniquely qualified for this position," said Dr. Elias Zerhouni, M.D., president of Sanofi Global R&D. "Nabel is working with other organizations, including providing guidance to researchers based on the company's extensive experience in vaccine and drug development, to determine how Sanofi can assist in making progress with this global challenge."

"Working with our colleagues across the industry, Sanofi is helping to find ways to advance medicines to prevent or treat Ebola virus infection. We also are sharing our scientific, medical, regulatory and manufacturing expertise with the World Health Organization, government and non-governmental organizations—public and private—in an effort to contain this epidemic,". Nabel said.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing